Magnetic resonance imaging detection of tumor cells by targeting low-density lipoprotein receptors with Gd-loaded low-density lipoprotein particles

被引:58
|
作者
Crich, Simonetta Geninatti
Lanzardo, Stefania
Alberti, Diego
Belfiore, Simona
Ciampa, Anna
Giovenzanaz, Giovanni B.
Lovazzano, Clara
Pagliarin, Roberto
Aime, Silvio
机构
[1] Univ Turin, Ctr Mol Imaging, I-10126 Turin, Italy
[2] Univ Turin, Dept Chem IFM, Turin, Italy
[3] Univ Turin, Dept Clin & Biol Sci, Orbassano, Italy
[4] Uni Piemonte Orientale, Dipartimento Sci Chim Alimentari Farmaceut & Farm, Novara, Italy
[5] Univ Milan, Dipartimento Chim Organ Ind, Milan, Italy
来源
NEOPLASIA | 2007年 / 9卷 / 12期
关键词
magnetic resonance imaging; LDL; Gd complexes; tumor; dual imaging probe;
D O I
10.1593/neo.07682
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gd-DO3A-diph and Gd-AAZTAC17 are lipophilic magnetic resonance imaging (MRI) agents that display high affinity for low-density lipoprotein (LDL) particles. However, on binding to LDL, Gd-DO3A-diph shows a decreased hydration that results in a lower enhancement of water proton relaxation rate. Conversely, Gd-AAZTAC17 displays a strong relaxation enhancement at the imaging fields. Each LDL particle can load up to 100 and 400 UNITS of Gd-DO3A-diph and Gd-AAZTAC17, respectively. Their LDL adducts are taken up by human hepatoblastoma G2 (HepG2) and melanoma B16 tumor cells when added to the incubation medium. T-1 measurements of the labeled cells indicate that Gd-AAZTAC17 is significantly more efficient than Gd-DO3A-diph. Furthermore, it has been found that HepG2 hepatoma cells can internalize higher amounts of Gd-AAZTAC17 than B16 cells and the involvement of LDL receptors (LDLRs) has been demonstrated in competition assays with free LDL. Gd-AAZTAC17/LDL adduct proved to be an efficient probe in the magnetic resonance (MR) visualization of subcutaneous tumors in animal models obtained by injecting B16 melanoma cells into the right flank of mice. Finally, confocal microscopy validation of the distribution of LDL-based probes in the tumor has been obtained by doping the Gd-AAZTAC17/LDL adduct with a fluorescent phospholipid moiety.
引用
收藏
页码:1046 / 1056
页数:11
相关论文
共 50 条
  • [31] THE LOW-DENSITY LIPOPROTEIN PATHWAY OF CULTURED LEYDIG TUMOR-CELLS - ULTILIZATION OF LOW-DENSITY LIPOPROTEIN-DERIVED CHOLESTEROL FOR STEROIDOGENESIS
    FREEMAN, DA
    ASCOLI, M
    BIOCHIMICA ET BIOPHYSICA ACTA, 1983, 754 (01) : 72 - 81
  • [32] Non-oxidative modification of native low-density lipoprotein by oxidized low-density lipoprotein
    Yang, M
    Leake, DS
    RiceEvans, CA
    BIOCHEMICAL JOURNAL, 1996, 316 : 377 - 380
  • [33] Fenofibrate lowers small low-density lipoprotein with no change in total low-density lipoprotein cholesterol
    Superko, HR
    Madan, S
    Tonnemacher, D
    Chronos, N
    Garrett, B
    Sheehan, D
    Raul, E
    Frohwein, S
    McGrath, K
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (06) : 316A - 316A
  • [34] Increased circulating oxidised low-density lipoprotein and antibodies to oxidised low-density lipoprotein in preeclampsia
    Arifin, Rosemawati
    Kyi, Win Mar
    Yaakob, Che Anuar Che
    Yaacob, Najib Majdi
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2017, 37 (05) : 580 - 584
  • [35] ACTIVATION OF LOW-DENSITY LIPOPROTEIN RECEPTOR SYNTHESIS BY TREATMENT WITH PARTIALLY DELIPIDATED LOW-DENSITY LIPOPROTEIN
    LEUNG, AM
    CHEUNG, WK
    HO, WKK
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY, 1983, 15 (07): : 929 - 934
  • [36] IS VERY LOW-DENSITY LIPOPROTEIN NECESSARY FOR FORMATION OF NORMAL SIZE LOW-DENSITY LIPOPROTEIN POPULATIONS
    DECKELBAUM, R
    OSCHRY, Y
    EISENBERG, S
    CARROLL, R
    RUDEL, L
    ARTERIOSCLEROSIS, 1982, 2 (05): : A437 - A437
  • [37] Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
    Katsiki, Niki
    Vrablik, Michal
    Banach, Maciej
    Gouni-Berthold, Ioanna
    PHARMACEUTICALS, 2023, 16 (04)
  • [38] Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment
    Lahoz, C
    Peña, R
    Mostaza, JM
    Laguna, F
    García-Iglesias, MF
    Taboada, M
    Pintó, X
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2005, 54 (06): : 741 - 747
  • [39] ACTIVATION OF LOW-DENSITY LIPOPROTEIN RECEPTOR SYNTHESIS BY TREATMENT WITH PARTIALLY DELIPIDATED LOW-DENSITY LIPOPROTEIN
    HO, WKK
    LEUNG, AM
    FEDERATION PROCEEDINGS, 1982, 41 (04) : 1217 - 1217
  • [40] Low-density lipoprotein particle size as an independent predictor of glycated low-density lipoprotein level
    Matsui, H
    Okumura, K
    Toki, Y
    Hayakawa, T
    DIABETES CARE, 1999, 22 (07) : 1220 - 1221